grant
Targeting the MET Pathway in Urothelial Carcinoma
Organization DIVISION OF BASIC SCIENCES - NCILocation UNITED STATES
NIHUS FederalResearch GrantFY20251-Phosphatidylinositol 3-KinaseAdnexa CarcinomaAdnexal CarcinomaAngiogenesis AntagonistsAngiogenesis BlockersAngiogenesis InhibitionAngiogenesis InhibitorsAngiogenetic AntagonistsAngiogenetic InhibitorsAngiogenic AntagonistsAngiogenic InhibitionAngiogenic InhibitorsAngiostatic AgentsAnti-Angiogenetic AgentsAnti-Angiogenic AgentsAnti-Angiogenic DrugsAnti-VEGFAnti-VEGF Humanized Monoclonal AntibodyAnti-VEGF RhuMAbAntiangiogenesis AgentsAntiangiogenic AgentsAntiangiogenic DrugsAvidityBellini Duct CarcinomaBindingBladderBladder AdenocarcinomaBladder Epidermoid CarcinomaBladder Squamous Cell CarcinomaBladder Urinary SystemBloodBlood Reticuloendothelial SystemCBDCACCRCD105CD105 AntigenCD105 GeneCDDPCancer cell lineCarboplatinCarboplatinoCell Communication and SignalingCell SignalingCell surfaceCheckpoint inhibitorCis-diammine-dichloroplatinumCis-diamminedichloridoplatinumCis-diamminedichloro Platinum (II)Cis-dichloroammine Platinum (II)Cis-platinous Diamine DichlorideCis-platinum IICis-platinum II Diamine DichlorideCisplatinCisplatinaCisplatinumClinicalClinical Treatment MoabClinical TrialsCollecting Duct CarcinomaCollecting Duct Type Renal Cell CarcinomaCollecting Ducts of Bellini CarcinomaCysplatynaDNA mutationDichlorodiammineplatinumDifluorodeoxycytidineDrugsDuctDuct (organ) structureEND GeneENG geneEPH- and ELK-Related Tyrosine KinaseEPH-and ELK-Related KinaseEndoglinEndoglin GeneEphrin Type-A Receptor 8Ephrin Type-A Receptor 8 PrecursorExtracellular Signal-Regulated Kinase GeneFLK1Genetic ChangeGenetic defectGenetic mutationGenitourinaryGenitourinary CancersGenitourinary systemHGF geneHGF/SFHHT1HHT1 GeneHepatocyte Growth FactorHepatopoietin AHistologicHistologicallyHistologyHumanIMiD3 cpdImmuneImmune checkpoint inhibitorImmunesImmunomodulationIntracellular Communication and SignalingKDR geneKidney Collecting Duct CarcinomaLiteratureLung Fibroblast-Derived MitogenMAP Kinase GeneMAPKMalignant Penile TumorMalignant neoplasm of penisMediatingMedicationMitogen-Activated Protein Kinase GeneMoAb VEGFModern ManMolecular InteractionMonoclonal AntibodiesMonoclonal Antibody Anti-VEGFMutationMyeloid-derived suppressor cellsNational Institutes of HealthNeovascularization InhibitorsNivolumabORW GeneORW1ORW1 GeneOpdivoPBMCPI-3 KinasePI3-KinasePI3CGPI3KGammaPI3kPIK3PIK3CGPIK3CG genePathway interactionsPatientsPenile CancerPeripheral Blood Mononuclear CellPeyrone's ChloridePeyrone's SaltPharmaceutical PreparationsPhase 2 Clinical TrialsPhase II Clinical TrialsPhosphatidylinositol 3-KinasePhosphatidylinositol-3-OH KinasePhosphoinositide 3-HydroxykinasePlatinum DiamminodichloridePropertyProtein Tyrosine KinaseProtein Tyrosine Kinase EEKProteinsPtdIns 3-KinaseRNA SeqRNA sequencingRNAseqRecombinant Humanized Anti-VEGF Monoclonal AntibodyRecombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth FactorRegulatory T-LymphocyteRenal Collecting Duct CarcinomaRenal Medullary CarcinomaRhuMAb VEGFScatter FactorScienceSeriesSignal PathwaySignal TransductionSignal Transduction SystemsSignalingSkin Appendage CarcinomaSmall Cell CancerSmall Cell CarcinomaTherapeutic TrialsTransforming Growth Factor P Receptor IIITransitional CarcinomaTransitional Cell CarcinomaTregType I Phosphatidylinositol KinaseType III Phosphoinositide 3-KinaseTyrosine KinaseTyrosine-Protein Kinase Receptor EEKTyrosine-Specific Protein KinaseTyrosylprotein KinaseUnited States National Institutes of HealthUrethraUrinary Bladder AdenocarcinomaUrinary Bladder Epidermoid CarcinomaUrinary Bladder Squamous Cell CarcinomaUrineUrogenitalUrogenital CancerUrogenital SystemUrothelial CarcinomaUrotheliumVEGF ReceptorsVEGFRVEGFR-2VEGFR2VPF ReceptorVascular Endothelial Cell Growth Factor ReceptorVascular Endothelial Growth Factor Receptor 2Vascular Permeability Factor ReceptorYervoyadvanced diseaseadvanced illnessangiogenesisantiangiogenicbevacizumabbiological signal transductionbonecancer progressioncancers that are rarechemotherapycis dichlorodiammineplatinumcis platinum compoundcis-Diaminedichloroplatinumcis-Diamminedichloroplatinumcis-Diamminedichloroplatinum(II)cis-Dichlorodiammineplatinum(II)cis-PlatinumcohortdFdCdFdCyddrug/agentexome sequencingexome-seqgemcitabinegenome mutationhydroxyaryl protein kinaseimmune check point inhibitorimmune modulationimmune regulationimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimmunosuppressive myeloid cellsipilimumablenalidomidemAbsmonoclonal Absmyeloid suppressor cellsmyeloid-derived suppressive cellsneoplasm progressionneoplastic progressionpathwayphase 2 studyphase II protocolphase II studyrare cancerrare malignancyrare tumorrecruitregulatory T-cellsresponserhuMabVEGFsmall molecular inhibitorsmall molecule inhibitorsuppressive myeloid cellstargeted agenttranscriptome sequencingtranscriptomic sequencingtumortumor growthtumor progressiontyrosyl protein kinaseurethralurinary bladder
Description preview
ICONIC-A phase 2 study of Ipilimumab, CabOzantinib, and NIvolumab in rare genitourinary (GU) cancers (ICONIC). This study includes 12 cohorts: bladder squamous cell carcinoma, bladder small cell carcinoma, bladder adenocarcinoma, bladder plasmacytoid, bladder sarcomatoid, urethra (all histologies), penile cancer, sarcomatoid RCC, collecting duct…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click